SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer
• SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target;
• SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026;
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). The data highlight SOT109's promising activity and tolerability profile across multiple disease models, reinforcing its potential to become a best-in-class therapeutic for the treatment of colorectal cancer and other gastrointestinal (GI) cancers. The findings were presented at the 15th World ADC London 2025, taking place from March 3 to 6 at Novotel London West, London, UK.
SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target
- SOT109 will leverage antibodies generated with Biocytogen’s proprietary RenMabTM platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers;
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics. The license will be used to develop an innovative antibody drug conjugate (ADC) for a novel tumor target under the option and license agreement established between the companies. The antibody selected will support the development of SOT109, SOTIO’s new ADC candidate, for the treatment of colorectal cancer and other gastrointestinal (GI) cancers.
SOTIO Showcases New Data on SOT201 Immunocytokine, VICTORIA-01 Clinical Study, and BOXR CAR-T Advancements at 2024 SITC Annual Meeting
- Global VICTORIA-01 Phase 1 study evaluating safety and efficacy of SOT201 in advanced solid tumor patients currently enrolling;
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced data supporting SOT201, its next-generation PD-1-targeting immunocytokine. The company also reported advancements in its BOXR cell therapy platform, introducing an innovative chimeric PGC-1α transgene to boost CAR T cell efficacy in patients with solid tumors. SOTIO will be presenting three posters highlighting these advancements at the 2024 Society for Immunotherapy of Cancer Meeting, taking place November 6–10 in Houston, TX, U.S.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
